---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-135766"
form_type: "8-K"
ticker: "ATYR"
cik: "0001339970"
company_name: "aTYR PHARMA INC"
filed_at: "2024-12-12T23:59:59+00:00"
generated_at: "2026-05-29T03:58:23.384603+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# aTyr Pharma appoints Eric Benevich to board; amends director compensation policy

## Summary
- Eric Benevich appointed as Class II director effective Dec 10, 2024, term through 2026 annual meeting.
- Granted option to purchase 100,000 shares at Dec 10 closing price, vesting equally over 36 months.
- Amended Non-Employee Director Compensation Policy: annual retainer $40,000; committee fees $5,000–$20,000.
- Initial equity grant for new non-employee directors set at 100,000 options; annual grant 50,000 options.

## SEC filing metadata
- accession: 0000950170-24-135766
- form_type: 8-K
- ticker: ATYR
- cik: 0001339970
- company_name: aTYR PHARMA INC
- filed_at: 2024-12-12T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1339970/000095017024135766/0000950170-24-135766-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1339970/000095017024135766/atyr-20241210.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-135766
- JSON: https://secwatch.observer/filing/0000950170-24-135766.json
- Plain text: https://secwatch.observer/filing/0000950170-24-135766.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.